Skip to Content
  • Previous Rank
    246
  • Revenues ($M)
    $39,807
  • Revenue Percent Change
    0.8%
  • Profits ($M)
    $3,920
  • Profits Percent Change
    -11.8%
  • Assets ($M)
    $95,377
  • Employees
    68,000

Merck brought in $39.8 billion in 2016 global sales. The U.S. drug giant’s wide-ranging portfolio was crucial to that haul–but the company’s next-generation cancer immunotherapy treatment, Keytruda, is what really set it apart last year. The therapy bested rival Bristol-Myers Squibb’s competing Opdivo in the critical lung cancer space, according to clinical trial data, making it (and Merck) one of the most formidable players in the latest strike on cancer.

Company Information

CEO
Kenneth C. Frazier
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Kenilworth, NJ
Websitehttp://www.merck.com
Years on Global 500 List23
Employees68,000
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

Merck Rank History

placeholder

Key Financials (Last Fiscal Year)

($ Millions)% change
Revenues ($M)$39,8070.8%
Profits ($M)$3,920-11.8%
Assets ($M)$95,377-
Total Stockholder Equity ($M)$40,088-

Profit Ratios

Profit as % of Revenues9.8%
Profits as % of Assets4.1%
Profits as % of Stockholder Equity9.8%